News - Telix Investors Alerted: Act by Jan. 9 in Suit Over SEC and FDA Findings

Hagens Berman, a prominent shareholder rights law firm, highlights a critical deadline for Telix Pharmaceuticals Ltd. (NASDAQ: TLX) investors concerning a securities class action lawsuit. The lawsuit stems from severe regulatory challenges, such as an SEC subpoena and an FDA Complete Response Letter (CRL), leading to a dramatic stock decline, prompting a 21% plunge. This legal action accuses Telix of allegedly exaggerating the developmental progress of its key prostate cancer therapy, TLX591. The company is also cited for misrepresentation regarding the regulatory compliance and reliability of its third-party manufacturers. Reed Kathrein, the partner spearheading Hagens Berman's investigation, underscores a 'dual regulatory failure' that questions the integrity of Telix’s public disclosures. The SEC investigation probed the authenticity of development claims made about TLX591, while the FDA’s CRL flagged significant Chemistry, Manufacturing, and Controls (CMC) deficiencies, issuing Form 483 notices to two manufacturing partners. These alleged regulatory oversight failures and concealed issues reportedly caused the company’s shares to nosedive in value, with investors experiencing considerable losses. Those investors who acquired Telix ADSs during the specified Class Period (Feb. 21, 2025 - Aug. 28, 2025) are being urged to contact Hagens Berman before the January 9, 2026 deadline to discuss their rights and potential lead plaintiff position. The lawsuit seeks to rectify investor damages through substantial recoveries, aligning with Hagens Berman's reputation for securing notable outcomes in investor fraud cases. The firm invites affected shareholders and those with insider knowledge to join their efforts by contacting Reed Kathrein directly or exploring whistleblower opportunities through the SEC’s program. Hagens Berman’s distinct history in plaintiff litigation and corporate accountability may provide a pathway for recovery to investors who have suffered losses under misleading corporate practices. The firm encourages all parties to consider their stance carefully as the deadline approaches, ensuring their voices and claims are addressed. For more details and to submit potential losses, investors are directed towards Hagens Berman's secure submission portal or to contact Kathrein's office directly for personalized guidance. This initiative aims to seek justice for those impacted by alleged oversights and misinformation perpetuated by Telix.